Danny Kharazmi


Admitted to the Ontario Bar: 2014

Print Bio

Instructions: Select the fields that you wish to include in the pdf generation.

% size of the Font for Generated PDF (Default is 80%)

*Practising as a professional corporation
  • Bio
  • Awards & Recognition
  • Professional Involvement
  • Representative Matters
  • Selected Publications
  • Insights
  • Education

Danny thrives on finding effective and creative solutions to help clients navigate through highly-regulated industries. By carefully considering the needs and goals of his clients, he provides an array of value-added solutions in relation to securities and corporate law matters.

Danny is a member of the firm’s Capital Markets, Corporate/Commercial and Mergers & Acquisitions/Private Equity Groups. He has expertise in a broad range of transactions and has led complex going public transactions and mergers and acquisitions. Danny is a trusted advisor to public and private companies, guiding them through all aspects of the startup phase, going public and transformational transactions. He also regularly advises members of senior management and boards of directors on continuous disclosure obligations and corporate governance matters.

Danny advises both public and private issuers in a broad range of industries, including biotech, esports, Fintech, mining and cannabis.

Danny is also an adjunct professor at Osgoode Hall Law School.

Awards & Recognition

  • Recognized in Best Lawyers: Ones to Watch in Canada in Securities Law 
  • Recognized in the Global Top 200 Psychedelics Lawyers Directory 2022 and 2023

Professional Involvement


Law Society of Ontario

Representative Matters

Represented Cybin Inc., a life sciences company focused on psychedelic pharmaceutical therapies, in the completion of a US$30 million common share purchase agreement.

Represented Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, in the completion of an overnight marketed offering pursuant to a prospectus supplement to Cybin's short form base shelf prospectus, with aggregate gross proceeds of approximately $34 million.

Represented Small Pharma Ltd, a U.K.-based neuropharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, in its acquisition by Small Pharma Inc. (formerly Unilock Capital Corp.) (TSXV: DMT) by way of a qualifying transaction and its related brokered and non-brokered private placements for aggregate gross proceeds of $63 million and initial TSX Venture Exchange listing.

Represented Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, in the completion of a bought deal short form prospectus offering of units for aggregate gross proceeds of approximately $34 million.

Represented Cybin Inc. (the “Company”) (NEO: CYBN) in the completion of its reverse takeover of Clarmin Explorations Inc. pursuant to the terms of an amalgamation agreement among Cybin Corp., Clarmin and a wholly-owned subsidiary of the Company as well as a private placement offering of 60 million subscription receipts for aggregate gross proceeds of $45 million.

Selected Publications

Co-author, "A New Era for the CSE: What Issuers Need to Know," Aird & Berlis LLP, May 2, 2023.

"Legal and Regulatory Landscape for Psychedelics Companies Considering Going Public in Canada," Aird & Berlis LLP's Capital Markets Newsletter, July 8, 2020. 


  • JD, University of Ottawa, 2013
  • MBA, University of Ottawa, 2013
  • MPA, Queen's University, 2006
  • BA (Honours), University of Toronto, 2005